Zydus Cadila Joins IO Therapy League With XOMA Tie-up

IL-2 Therapy Use So Far Limited By Toxicities

 
• By Vibha Ravi
  
Generate a summary of this article
Listen to this article
Beta

Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody

Perfect business partnership as a connecting puzzle shaped as two trees in the form of human heads connecting together as a corporate success metaphor for cooperation and agreement as equal partners.
Cadila And XOMA Hope Their Combination Will Be A Win-Win • Source: Shutterstock

Cadila Healthcare Ltd., the flagship firm of India's Zydus Cadila group, has entered the league of companies researching interleukin (IL) therapies through a tie-up with Emeryville, California-based Xoma Corp. for an immuno-oncology (IO) drug candidate that combines Zydus’s IL-2 product with XOMA’s novel anti-IL-2 monoclonal antibody.

Cadila will conduct clinical trials for the IL-2 therapy and have exclusive rights to develop and commercialize this in India,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.